09 24 21 -- 5 Misconceptions About Data Integrity In Pharma pharmaceuticalonline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmaceuticalonline.com Daily Mail and Mail on Sunday newspapers.
Evonik and Cassava Sciences join forces to fight Alzheimer’s disease
Evonik to supply commercial quantities of simufilam, a drug candidate for the treatment of Alzheimer’s disease
The late clinical phase quantities will be produced at Evonik’s Tippecanoe site in Indiana, USA
Evonik is recognized as one of the largest contract manufacturing organizations (CMO)
Essen, Germany. Evonik has entered into a supply agreement with Cassava Sciences, a clinical-stage biotechnology company focused on neuroscience. Evonik will supply Cassava Sciences with large-scale, clinical-grade quantities of simufilam, a drug candidate for the treatment of Alzheimer’s disease.
“We are delighted to be collaborating with Cassava and contributing to fight Alzheimer’s together. We are committed to supporting Cassava in their goals to maintain the quality of life for millions of patients around the world and to further advance potential treatment options”, said Thomas Riermeier, head o
Advantages In The Continuous Manufacturing Of APIs And Intermediates Under cGMP Conditions
Interview with Dr. Andreas Meudt, Head of Exclusive Synthesis, Evonik
At least seven drug products utilizing continuous manufacturing processes have been approved by the FDA to-date, with many others in clinical development. However, when it comes to APIs and advanced intermediates, there are few pharmaceutical companies that have successfully utilized continuous manufacturing for more than a single process step. In addition, very few have been able to scale-up beyond the kilogram range under cGMP conditions. In this interview with Dr. Andreas Meudt, Head of Exclusive Synthesis for Evonik, the challenges and opportunities for the use of continuous manufacturing for APIs and intermediates are reviewed.